Rakovina Therapeutics Inc ( (TSE:RKV) ) has shared an announcement.
Rakovina Therapeutics Inc. has announced a significant milestone in its AI-driven drug discovery efforts, receiving the first synthesized batch of ATR inhibitor compounds developed with Variational AI. These compounds, targeting DNA repair deficiencies in cancers like ovarian, breast, and prostate, are set to enter preclinical testing. This advancement highlights Rakovina’s commitment to leveraging AI for rapid drug development, particularly for hard-to-treat central nervous system malignancies, filling a gap in the current lack of FDA-approved ATR inhibitors.
More about Rakovina Therapeutics Inc
Rakovina Therapeutics Inc. is a biopharmaceutical research company focused on developing innovative cancer treatments. The company utilizes unique technologies targeting the DNA-damage response, powered by Artificial Intelligence (AI) through proprietary platforms such as Deep-Docking™ and Enki™. Rakovina aims to advance drug candidates into human clinical trials in collaboration with pharmaceutical partners.
YTD Price Performance: -27.78%
Average Trading Volume: 289,602
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$13.54M
See more insights into RKV stock on TipRanks’ Stock Analysis page.